Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 501-510 of 2796 for

Edit search filters
  1. A Study Of Sonodynamic Therapy With SONALA-001 And Exablate 4000 Type 2.0 In Subjects With Progressive Or Recurrent Glioblastoma Multiforme (RGBM)

    Rochester, MN

  2. Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer

    Rochester, MN

  3. A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma

    Rochester, MN

  4. Efineptakin alfa (NT-I7) Plus Pembrolizumab for the Treatment of Recurrent Glioblastoma

    Rochester, MN

  5. DALY 2.0 USA/​ MB-CART2019.1 for DLBCL

    Scottsdale/Phoenix, AZ, Rochester, MN

  6. Testing the Addition of a New Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

    Jacksonville, FL, Rochester, MN

  7. NRG-GY012 “A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, And The Combinations Of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5356 (Capivasertib) In Women With Recurrent, Persistent Or Metastatic Endometrial Cancer. A Multi-Arm Trial For Women With Recurrent Or Persistent Endometrial Cancer”

    Scottsdale/Phoenix, AZ, Eau Claire, WI, Rochester, MN

  8. Selection Of Allogeneic Hematopoietic Cell Donors Based On KIR And HLA Genotypes

    Rochester, MN

  9. First In Human Study Of KO-539 To Treat Relapsed Or Refractory Acute Myeloid Leukemia

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  10. A Study Of Berubicin In Adult Subjects With Recurrent Glioblastoma Multiforme

    Jacksonville, FL, Rochester, MN

.

Mayo Clinic Footer